Alrex (loteprednol etabonate opthalmic suspension 0.2%) / Bausch Health - LARVOL DELTA

Treatment of allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Dex-AC: DEXTENZA Therapy for Treatment of Allergic Conjunctivitis (clinicaltrials.gov) - P4 | N=31 | Completed | Sponsor: Clinical Research Center of Florida | Not yet recruiting ➔ Completed

Trial completion • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Loteprednol 0.25% (Eysuvis) for dry eye disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dry Eye Disease • Ophthalmology

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis (clinicaltrials.gov) - P4; N=30; Not yet recruiting; Sponsor: Clinical Research Center of Florida

New P4 trial • Conjunctivitis • Ocular Inflammation • Ophthalmology

"I #vote with you @biljana_parapid : Team #RadialRex" (@alxbenevides)

A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis (clinicaltrials.gov) - P4; N=20; Completed; Sponsor: Zhongshan Ophthalmic Center, Sun Yet-sen University

New P4 trial • Biosimilar • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

"Thai central bank says ready to curb resilient baht if needed https://t.co/TMkmalrExV" (@Reuters)

Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. (PubMed, Addict Biol) - "However, a pharmacovigilance database of more than 260 000 alcohol-dependent patients treated with sodium oxybate reported very few adverse side effects and only few cases of abuse. We therefore conclude that sodium oxybate is an effective, well-tolerated and safe treatment for withdrawal and relapse prevention treatment, especially in alcohol-dependent patients with VH DRL."

Clinical • Journal

Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium (clinicaltrials.gov) - P4; N=108; Completed; Sponsor: Wannisa Suphachearabhan

Clinical • New P4 trial

Discover Lotemax SM (Cvent)

Live event

Pathogenesis of myeloproliferative neoplasms: insights from mouse models (PubMed, Rinsho Ketsueki) - "One of the main molecular features of myeloproliferative neoplasms (MPNs) is the high frequency of JAK2V617F or CALRexon 9 mutations...The mutation landscape of hematological tumors has already been clarified using next-generation sequencing technology, and future research on the importance of the functional analysis of mutant genes in vivo should be emphasized. Thus, it is necessary to promote rapid genetic modification techniques such as genome editing."

Journal • Preclinical

Dry-eye therapies: What’s next? (Review of Ophthalmology) - "Karl G. Stonecipher, MD, and his colleagues are conducting a retrospective review combining low-level light therapy with intense pulsed light using a new device....'The low-level light therapy or photobiomodulation basically heats the glands endogenously, and it’s combined with no-gel IPL,' Dr. Stonecipher says....'We have some exciting times ahead,' Dr. Sheppard says. 'We have a couple of drugs that will be out in the next year or two, and then a slew of drugs will be coming out in the next three to five years.' Dr. Pflugfelder is more circumspect. 'I think eventually there will be new classes of drugs that may be more effective than what we have right now,' he says."

Media quote